Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) reported its third quarter 2020 results alongside a corporate update, highlighting an agreement with the FDA to move the BLA submission for lifileucel to 2021. The company initiated a registration-directed study for lung cancer and reported strong financials with $719.7 million in cash. However, net losses increased to $58.6 million in Q3 2020. R&D expenses grew due to clinical trials and internal team expansion. Iovance aims to lead in TIL therapy development and is set to present data at the SITC Annual Meeting.

Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q3 2020 financial results on November 5, 2020, followed by a conference call at 4:30 p.m. EST for a corporate update. The company focuses on T cell-based cancer immunotherapies, and its pivotal studies include treatments for metastatic melanoma and advanced cervical cancer. Iovance aims to enhance patient care by making immunotherapies accessible for various cancers. Key challenges may impact clinical trial timelines and regulatory approvals, particularly due to COVID-19 and potential FDA feedback.

Iovance Biotherapeutics, a late-stage biotechnology company focused on T cell-based cancer immunotherapies, announced its participation in several upcoming conferences in November 2020. Key events include the Next Generation CAR and T Cell Therapies Conference on Nov. 2, the Credit Suisse 29th Annual Virtual Healthcare Conference on Nov. 9, and the SITC Annual Meeting from Nov. 9-14, featuring a presentation on tumor infiltrating lymphocytes for advanced cancers. Archived webcasts will be available on the Iovance website.

Iovance Biotherapeutics announced new interim data for its tumor infiltrating lymphocyte therapy, LN-145, combined with pembrolizumab for treating head and neck squamous cell carcinoma (HNSCC). This data will be presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 9-14, 2020. The therapy employs a patient's own immune cells to combat cancer, with ongoing studies in metastatic melanoma and advanced cervical cancer, showcasing the company's commitment to enhancing patient care with innovative T cell-based immunotherapies.

Iovance Biotherapeutics, a biotechnology firm focused on cancer immunotherapies, announced participation in two upcoming virtual conferences. On October 6, 2020, the company will present at the Jefferies Cell Therapy Summit at 3:00 p.m. EDT, with a webcast available on their website. Following this, from October 12-16, 2020, they will present at the Alliance for Regenerative Medicine Meeting on the Mesa, with presentations available on demand starting October 12. Iovance specializes in TIL therapy for solid tumors and blood cancers.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced a regulatory update regarding its TIL therapy, lifileucel, for metastatic melanoma. Following discussions with the FDA, the company is refining potency assays required for its Biologics License Application (BLA) submission, which is now expected in 2021 instead of 2020. Clinical trial data shows lifileucel has an overall response rate of 36.4% in Cohort 2, compared to 4-10% for current chemotherapy options. The company emphasizes urgency in addressing unmet patient needs while working closely with the FDA to finalize regulatory requirements.

Iovance Biotherapeutics, a late-stage biotechnology firm, will present at the BTIG Biotechnology Conference 2020 on August 11 at 2:30 PM ET. The event will focus on their T cell-based cancer immunotherapies, particularly Tumor Infiltrating Lymphocyte (TIL) therapy for solid tumors and blood cancers. The company is conducting pivotal studies in metastatic melanoma and advanced cervical cancer, and its TIL therapies are being explored for various cancers. A live webcast will be available on their investor website.

Iovance Biotherapeutics (NASDAQ: IOVA) reported its second quarter 2020 financial results, showing a cash position of $777.4 million as of June 30, compared to $312.5 million at the end of 2019. The net loss was $63 million or $0.47 per share, reflecting an increase from $47.6 million in Q2 2019. Clinical progress includes positive data from the melanoma program for lifileucel, supporting a planned BLA submission. Enrollment completed for cervical cancer studies, with ongoing preparations for commercial launch and CLL/SLL studies.

Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q2 2020 financial results on August 6, 2020, followed by a conference call at 4:30 p.m. EDT. The company, focused on T cell-based cancer therapies, is advancing its pivotal studies for metastatic melanoma and advanced cervical cancer. Iovance’s Tumor Infiltrating Lymphocyte (TIL) therapy aims to leverage patients' own immune cells to combat cancer. The company is also exploring PBL therapy for blood cancers. More information can be found on their website.